open access

Vol 8, No 4 (2012)
Case report
Published online: 2012-10-08
Get Citation

Response to third line hormonotherapy (fulvestrant) in patient with metastatic breast cancer after the f

Katarzyna Gabalewicz, Marcin Ekiert, Emilia Filipczyk-Cisarż
Onkol. Prak. Klin 2012;8(4):151-154.

open access

Vol 8, No 4 (2012)
CASE REPORT
Published online: 2012-10-08

Abstract

Hormonotherapy is an effective palliative treatment in patients with metastatic, hormone-dependent breast
cancer, which improves the quality of life of these patients. Next line hormonotherapy is considered to be
reasonable in the case of good efficacy of primary hormonal treatment. Clinical observations indicate the
potential benefit of returning to the hormonotherapy even if the first line fails. The paper presents a case
of a patient who has achieved long-term clinical response to therapy with fulvestrant, despite the failure
of treatment with aromatase inhibitors.

Abstract

Hormonotherapy is an effective palliative treatment in patients with metastatic, hormone-dependent breast
cancer, which improves the quality of life of these patients. Next line hormonotherapy is considered to be
reasonable in the case of good efficacy of primary hormonal treatment. Clinical observations indicate the
potential benefit of returning to the hormonotherapy even if the first line fails. The paper presents a case
of a patient who has achieved long-term clinical response to therapy with fulvestrant, despite the failure
of treatment with aromatase inhibitors.
Get Citation
About this article
Title

Response to third line hormonotherapy (fulvestrant) in patient with metastatic breast cancer after the f

Journal

Oncology in Clinical Practice

Issue

Vol 8, No 4 (2012)

Article type

Case report

Pages

151-154

Published online

2012-10-08

Bibliographic record

Onkol. Prak. Klin 2012;8(4):151-154.

Authors

Katarzyna Gabalewicz
Marcin Ekiert
Emilia Filipczyk-Cisarż

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl